EN | UA
EN | UA

Help Support

Back

A study compared two drugs in combination with methotrexate in RA patients

A study compared two drugs in combination with methotrexate in RA patients A study compared two drugs in combination with methotrexate in RA patients
A study compared two drugs in combination with methotrexate in RA patients A study compared two drugs in combination with methotrexate in RA patients

What's new?

Though leflunomide-methotrexate combination was found to be as effective as a low-dose rituximab-methotrexate combination, it still could be a treatment of choice due to its cost-effectiveness.

The results from a randomized, double-blind controlled clinical trial showed that Leflunomide-methotrexate combination is as efficacious as the low-dose rituximab-methotrexate combination at 24 weeks, in RA patient's refractory to initial DMARDs.

Rheumatoid Arthritis is a systemic inflammatory condition resulting in joint damage with reduced locomotion. The standard dose of rituximab prescribed for rheumatoid arthritis (RA) is 1000 mg. But certain current studies showed that a low dose of rituximab (500 mg) is also effective. The efficacy of low dose rituximab in rheumatoid arthritis (RA) refractory to first-line non-biologic DMARDs, compared to leflunomide was unknown.

Thus, a clinical trial was conducted to compare the efficacy and safety of low-dose rituximab-methotrexate combination with the leflunomide-methotrexate combination.
In the current study patients on methotrexate (10-20 mg/week) with a Disease Activity Score (DAS) > 3.2 were randomly provided rituximab (500 mg on days 1 and 15) or leflunomide (10-20 mg/day). The primary end-point was ACR20 at 24 weeks. A sample of 40 had 70% power to detect a 30% difference. The secondary endpoints were ACR50, ACR70, DAS, EULAR good response, CD3 + (T cell), CD19 + (B cell) and CD19 + CD27+ (memory B cell) counts, pneumococcal and tetanus antibody levels.
The findings showed that baseline characteristics were comparable in the two groups. At week 24, ACR20 was 85% vs 84%, ACR50 was 60% vs. 64% and ACR70 was 35% vs 32%, in rituximab and in leflunomide groups respectively. SAEs were similar. But with rituximab, there was a significant reduction in B cells, memory B cells and pneumococcal antibody levels without significant changes in T cells and tetanus antibody levels at 24 weeks. With leflunomide, a significant reduction in memory B cells and pneumococcal antibody levels occurred without significant changes in B cells, T cells or tetanus antibody levels.

Changes in immune response parameters with leflunomide are novel and need further characterisation.

Source:

BMC Musculoskelet Disord. 2017 Jul 19;18(1):310.

Article:

Leflunomide is equally efficacious and safe compared to low dose rituximab in refractory rheumatoid arthritis given in combination with methotrexate: results from a randomized double blind controlled clinical trial.

Authors:

Harindu Wijesinghe et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en
Try: